Sedation in PICU

Principles of Sedation in the Intensive Care Unit

Provide safe and effective control of pain, anxiety, and motion to allow necessary therapeutic and diagnostic procedures.
Ensure appropriate amnesia and decreased awareness of the intensive care environment.
Facilitate mechanical ventilation by improving patient-ventilator synchrony and overcoming patient-ventilation dys-synchrony.
Decrease systemic or myocardial oxygen consumption and metabolic demand (e.g., in septic shock, cardiogenic shock, or severe acute respiratory distress syndrome).
Blunt the physiologic stress response, which can trigger systemic inflammatory response syndrome (SIRS).

Sedation exists on a continuum governed by the American Society of Anesthesiologists (ASA) guidelines, ranging from anxiolysis to general anesthesia.

Level of Sedation	Clinical Characteristics	Airway and Ventilation	Cardiovascular Function
Minimal Sedation (Anxiolysis)	Drug-induced state where the patient responds normally to verbal commands. Cognitive function/coordination may be impaired.	Airway patent; spontaneous ventilation unaffected.	Unaffected.
Moderate Sedation (Conscious Sedation)	Depression of consciousness. Purposeful response to verbal commands, alone or with light tactile stimulation.	No interventions required for airway. Spontaneous ventilation is adequate.	Usually maintained.
Deep Sedation/Analgesia	Depression of consciousness. Cannot be easily aroused but responds purposefully after repeated/painful stimulation.	May require assistance to maintain a patent airway. Spontaneous ventilation may be inadequate.	Usually maintained.
General Anesthesia	Drug-induced loss of consciousness. Unarousable even to painful stimuli.	Requires assistance for patent airway. Positive pressure ventilation required.	May be impaired.

Detailed pre-sedation evaluation includes assessment of underlying medical problems, baseline vital signs, medication use, allergies, and fasting status.
Classification of the patient's physical status using the ASA scoring system is mandatory to predict sedation suitability and risks.

ASA Class	Description	Sedation Suitability
Class 1	Healthy patient (unremarkable past medical history).	Excellent.
Class 2	Mild systemic disease (e.g., controlled asthma, diabetes).	Generally good.
Class 3	Severe systemic disease with functional limitations.	Intermediate to poor (benefits relative to risks).
Class 4	Severe systemic disease that is a constant threat to life.	Poor (benefits rarely outweigh risks).
Class 5	Moribund patient not expected to survive without intervention.	Extremely poor.

Continuous monitoring of the child's face, mouth, and chest wall movement is essential.
Use of physiological monitors: Electrocardiogram (ECG), continuous pulse oximetry, and non-invasive/invasive blood pressure monitoring.
Objective assessment tools include the Bispectral Index (BIS) to assess the depth of sedation, especially in chemically paralyzed patients.
Clinical scoring systems are utilized to titrate medications, such as the COMFORT scale or the State Behavioral Scale (SBS) (target scores generally depend on the clinical requirement, e.g., SBS $- 1$ to $0$ for moderate sedation).

Initiate therapy with a single sedative drug (preferably midazolam) and adjust to achieve the desired level of sedation.
Combine with an analgesic (like fentanyl) since sedatives lack analgesic properties.
Utilize Daily Sedation Interruption (DSI) (e.g., withholding sedatives for 2 hours daily) to prevent complications of oversedation and assess readiness for extubation.
Prolonged continuous infusion ( $> 5 days$ ) of benzodiazepines or opioids leads to tolerance and physical dependence.
Weaning must be gradual (e.g., tapering by $10$ daily) to avoid Iatrogenic Withdrawal Syndrome (IWS).
Monitor withdrawal symptoms using validated tools like the Withdrawal Assessment Tool-1 (WAT-1) or the Sophia Observation withdrawal Symptoms-scale (SOS).

Mechanism of Action: Gamma-aminobutyric acid (GABA) agonists.
Effects: Induce hypnosis, anxiolysis, sedation, amnesia, and act as anticonvulsants.
Midazolam: Water-soluble, short-acting, and most commonly used in the pediatric ICU. It can be given intravenously (IV), orally, intranasally, or intramuscularly.
Diazepam / Lorazepam: Lorazepam has no active metabolites, making it useful in certain systemic dysfunctions.
Side Effects: Dose-dependent respiratory depression (synergistic with opioids), systemic hypotension, and risk of tolerance/withdrawal.

Dexmedetomidine: Central $α_{2}$ agonist that provides anxiolysis, sedation, mild analgesia, and sympatholysis without causing respiratory depression.
- Allows patients to remain in a more easily arousable and cooperative state, useful for non-invasive ventilation (NIV) or extubation.
- Side effects include bradycardia and hypotension with continuous infusions, or initial hypertension with rapid boluses.
Clonidine: Often used as an adjunct or transition agent during the weaning of dexmedetomidine and opioids.

Ketamine: An NMDA receptor antagonist that dissociates the cerebral cortex from the limbic system.
Effects: Provides simultaneous hypnosis, profound analgesia, and amnesia.
Advantages: Preserves spontaneous respiratory drive, airway reflexes, and cardiac output. It is a potent bronchodilator, making it the sedative of choice for intubated children with acute severe asthma.
Side Effects: Increases myocardial oxygen demand, heart rate, and blood pressure. It acts as a secretagogue (causes sialorrhea, necessitating anticholinergics like glycopyrrolate) and may cause emergence delirium/hallucinations. Associated with increased intracranial pressure (ICP), requiring caution in traumatic brain injury.

Mechanism of Action: Rapid-acting IV hypnotic and amnestic agent with no analgesic properties.
Advantages: Very short half-life allows for rapid awakening. Acts as an antiemetic and reduces ICP.
Side Effects: Causes potent dose-dependent respiratory depression, apnea, and vasodilation (hypotension).
Propofol Infusion Syndrome (PRIS): Prolonged infusions ( $> 24 - 48 hours$ ) or high doses can cause a fatal syndrome characterized by cardiac failure, metabolic acidosis, rhabdomyolysis, and renal failure. Its prolonged use is contraindicated in pediatric ICUs.

Agents: Thiopental and Pentobarbital.
Indications: Primarily used for induction of anesthesia or management of refractory status epilepticus and severe intracranial hypertension (barbiturate coma).
Side Effects: Potent myocardial depressants causing severe hypotension, apnea, and respiratory depression. They lack analgesic effects and have a prolonged half-life, causing delayed emergence.

Drug	Class	Continuous Infusion Dose
Midazolam	Benzodiazepine	$1 - 5 mcg/kg/min$ IV
Dexmedetomidine	$α_{2}$ Agonist	$0.25 - 1.25 mcg/kg/h$ IV
Propofol	Hypnotic	$1 - 6 mg/kg/h$ IV (Short-term only)
Ketamine	Dissociative Anesthetic	$0.5 - 1 mg/kg/h$ IV
Clonidine	$α_{2}$ Agonist	$1 - 3 mcg/kg/h$ IV
Fentanyl	Opioid Analgesic	$1 - 5 mcg/kg/h$ IV (Used in combination)

Neuromuscular blocking agents (NMBAs) such as vecuronium or rocuronium produce akinesia but absolutely no hypnosis, amnesia, or analgesia.
If a child is receiving NMBAs to facilitate mechanical ventilation, it is mandatory to simultaneously provide deep sedation and analgesia to prevent the psychological trauma of being awake but paralyzed.